Dear reader,
This issue of Human Vaccines & Immunotherapeutics starts with five articles on Immunotherapy: multi-omics characterization of a metastatic melanoma patient with durable remission following dendritic cell (DC) vaccination (Dillman, p 742), in vitro (Ma, p 756) and in vivo (George, p 779) evaluation of novel DC-targeting hepatitis B chimeric protein immunotherapy, a preclinical study on an intranasal cocktail of MAbs for treatment of ricin poisoning (Rong, p 793), and a meeting report from the 17th Annual Meeting of the Association for Cancer Immunotherapy (Beck, p 808).
The Influenza section features seven research articles on 2016-7 vaccine effectiveness against H3N2 and H1N1 strains in Chinese children (Zhang, p 816), impact of a school-based vaccination program in Hong Kong (Lau, p 823), consequences of switching from tri- to quadrivalent vaccine in Mexico (Ruiz-Palacios, p 827), direct and indirect effects of vaccinating children in Germany (Schmidt-Ott, p 836), potential connection between influenza vaccination and protection from heart disease (Musharrafieh, p 846), vaccine knowledge and attitudes among patients hospitalized with influenza-like illness (Tubiana, p 851), and immunogenicity and safety of high-dose quadrivalent vaccine in Japanese elderly (Sanchez, p 858).
Eight articles on Licensed Vaccines include a comparison of anti-hepatitis B and anti-pertussis antibodies in children vaccinated with different hexavalent vaccines (Vesikari, p 867), assessment of risk of fever following measles vaccine in children in relation to their parents’ medical condition (Zerbo, p 875), analysis of measles immunity in the China-Myanmar border region (Zhou, p 881), cost-effectiveness modelling study of various varicella vaccination strategies in Mexico (Graham, p 886), a report on rubella seroprevalence among Italian women (Marchi, p 895), a meeting report from the 5th European Society of Clinical Microbiology and Infectious Diseases conference (Esposito, p 899), a commentary on yellow fever vaccine in Brazil (Ishak, p 900), and a case report on immune persistence 10 years after rabies post-exposure prophylaxis in a child (Zhu, p 904).
The Novel Vaccines section presents a challenge study on a DNA vaccine-antibody combination for prevention of Zika infection (Choi, p 907), a review on the development of leishmaniasis vaccines (Coutinho de Oliveira, p 919), and a Letter to the Editor on the One Health approach to the current COVID-19 epidemic (Ahmad, p 931).
Two Meningococcal research articles discuss disparities in U.S. healthcare providers’ interpretation of ACIP recommendations (Huang, p 933) and protection by 4CMenB vaccine against strains not predicted by the Meningococcal Antigen Typing System (Stella, p 945).
Two research articles on Hepatitis B investigate the effectiveness of booster doses in healthcare workers (Grazzini, p 949) and the cost-effectiveness of adjuvant immunoglobulin treatment in universal vaccination settings in China (Zeng, p 955).
Finally, we are happy to present a report on Pneumococcal vaccine uptake among Australian elderly (Frank, p 965), a review of vaccine Clinical trials in Africa (Ndwandwe, p 972), analysis of HPV vaccine coverage in sexual minorities in Mexico (Allen-Leigh, p 981), and a Public Health review on adult vaccination in India (Dash, p 991).
Our monthly News, Policy and Profiles (NP&P) track offers a selection of the latest news in the field of vaccines and immunotherapeutics. In this section we also regularly publish opinion pieces on timely, interesting and controversial topics related to vaccines and immunotherapeutics, profiles of companies and organizations, as well as portraits of distinguished scientists in our field. Please contact Acquisitions Editor Adam Weiss ([email protected]) with your ideas for commentaries, opinion pieces, profiles and portraits. Your suggestions for and contributions to our N&P&P track are always welcome!
Sincerely,
Ronald Ellis, PhD
Editor-in-Chief
Adam Weiss, PhD
Acquisitions Editor